The drug, DS-5141, is a nucleic acid medicine and has been co-developed with Orrphan Disease Treatment Institute, Tokyo. As it was not possible to obtain the expected results with regard to the main endpoint of efficacy, the administration period for the same patient will be prolonged 4fold.
Daiichi Sankyo news release, April 25, 2018
Daiichi Sankyo extends phase I/II test on novel treatment of Duchenne muscular dystrophy (DMD)